Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
Alexander E. Perl(University of Pennsylvania), Jessica K. Altman(Northwestern University), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Catherine C. Smith(University of California, San Francisco), Mark R. Litzow(Mayo Clinic in Arizona), Maria R. Baer(University of Maryland, Baltimore), David F. Claxton(Penn State Milton S. Hershey Medical Center), Harry P. Erba(University of Alabama at Birmingham), Stan Gill(Astellas Pharma (United States)), Stuart L. Goldberg(Hackensack University Medical Center), Joseph G. Jurcic(Columbia University Irving Medical Center), Richard A Larson(University of Chicago), Chaofeng Liu(Astellas Pharma (United States)), Ellen K. Ritchie(Cornell University), Gary J. Schiller(University of California, Los Angeles), Alexander I. Spira(Virginia Cancer Specialists), Stephen A. Strickland(Vanderbilt University), Raoul Tibes(University of Würzburg), Celalettin Üstün(University of Minnesota), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Robert K. Stuart(Medical University of South Carolina), Christoph Röllig(Technische Universität Dresden), Andreas Neubauer(Universitätsklinikum Gießen und Marburg), Giovanni Martinelli(University of Bologna), Erkut Bahceci(Astellas Pharma (United States)), Mark J. Levis(Johns Hopkins University)
Cited by 488Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis